All Stories

  1. Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy

    Article • Current Medicinal Chemistry, June 2020, Bentham Science Publishers

    Ester Simeone, Francesco Marincola

  2. Nivolumab for the treatment of small cell lung cancer

    Article • Expert Review of Respiratory Medicine, October 2019, Taylor & Francis

    Ester Simeone, claudia trojaniello

  3. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

    Article • Expert Review of Clinical Pharmacology, January 2019, Taylor & Francis

    claudia trojaniello, Ester Simeone

  4. The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma

    Article • Expert Opinion on Therapeutic Targets, December 2018, Taylor & Francis

    Ester Simeone

  5. Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

    Article • Current Clinical Pharmacology, October 2018, Bentham Science Publishers

    Ester Simeone, FILIPPO DE MARINIS

  6. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

    Article • Pigment Cell & Melanoma Research, December 2017, Wiley

    Ester Simeone

  7. The state of the art of antibodies that block PD-1 in the trestment of metastic melanoma

    Article • Melanoma Management, November 2017, Future Medicine

    Ester Simeone

  8. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

    Article • Journal of the European Academy of Dermatology and Venereology, November 2017, Wiley

    Ester Simeone

  9. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?

    Article • Expert Opinion on Biological Therapy, March 2017, Taylor & Francis

    Ester Simeone

  10. Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

    Article • Cancer, February 2014, Wiley

    Ester Simeone

  11. Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon

    Article • Journal of Chemotherapy, December 2013, Taylor & Francis

    Ester Simeone